---
layout: post
title: "Ulcerative Colitis: Developing Drugs for Treatment; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:58:59 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-09237
original_published: 2022-04-29 00:00:00 +0000
significance: 8.00
---

# Ulcerative Colitis: Developing Drugs for Treatment; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** April 29, 2022 00:00 UTC
**Document Number:** 2022-09237

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Ulcerative Colitis: Developing Drugs for Treatment." This draft guidance addresses FDA's current thinking about necessary attributes of clinical trials for developing drugs for the treatment of ulcerative colitis in adults, including recommendations for trial population, trial design, and efficacy and safety considerations. This draft guidance replaces the draft guidance for industry entitled "Ulcerative Colitis: Clinical Trial Endpoints," which is being withdrawn.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/04/29/2022-09237/ulcerative-colitis-developing-drugs-for-treatment-draft-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2022-09237

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
